These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 25307878)

  • 61. Bromodomain Inhibitor JQ1 Provides Novel Insights and Perspectives in Rhabdomyosarcoma Treatment.
    Marchesi I; Fais M; Fiorentino FP; Bordoni V; Sanna L; Zoroddu S; Bagella L
    Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408939
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The BET PROTAC inhibitor GNE-987 displays anti-tumor effects by targeting super-enhancers regulated gene in osteosarcoma.
    Wu D; Yin H; Yang C; Zhang Z; Fang F; Wang J; Li X; Xie Y; Hu X; Zhuo R; Chen Y; Yu J; Li T; Li G; Pan J
    BMC Cancer; 2024 Aug; 24(1):928. PubMed ID: 39090568
    [TBL] [Abstract][Full Text] [Related]  

  • 63. BET and BRAF inhibitors act synergistically against BRAF-mutant melanoma.
    Paoluzzi L; Hanniford D; Sokolova E; Osman I; Darvishian F; Wang J; Bradner JE; Hernando E
    Cancer Med; 2016 Jun; 5(6):1183-93. PubMed ID: 27169980
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Ferritinophagy is required for the induction of ferroptosis by the bromodomain protein BRD4 inhibitor (+)-JQ1 in cancer cells.
    Sui S; Zhang J; Xu S; Wang Q; Wang P; Pang D
    Cell Death Dis; 2019 Apr; 10(5):331. PubMed ID: 30988278
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib.
    Sun B; Shah B; Fiskus W; Qi J; Rajapakshe K; Coarfa C; Li L; Devaraj SG; Sharma S; Zhang L; Wang ML; Saenz DT; Krieger S; Bradner JE; Bhalla KN
    Blood; 2015 Sep; 126(13):1565-74. PubMed ID: 26254443
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Sequential targeting of YAP1 and p21 enhances the elimination of senescent cells induced by the BET inhibitor JQ1.
    Zhang HT; Gui T; Liu RX; Tong KL; Wu CJ; Li Z; Huang X; Xu QT; Yang J; Tang W; Sang Y; Liu W; Liu N; Ross RD; He QY; Zha ZG
    Cell Death Dis; 2021 Jan; 12(1):121. PubMed ID: 33495462
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
    Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH
    Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Brd4 is essential for IL-1β-induced inflammation in human airway epithelial cells.
    Khan YM; Kirkham P; Barnes PJ; Adcock IM
    PLoS One; 2014; 9(4):e95051. PubMed ID: 24759736
    [TBL] [Abstract][Full Text] [Related]  

  • 69. EGFR signaling confers resistance to BET inhibition in hepatocellular carcinoma through stabilizing oncogenic MYC.
    Yin Y; Sun M; Zhan X; Wu C; Geng P; Sun X; Wu Y; Zhang S; Qin J; Zhuang Z; Liu Y
    J Exp Clin Cancer Res; 2019 Feb; 38(1):83. PubMed ID: 30770740
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Inhibition of bromodomain proteins for the treatment of human diffuse large B-cell lymphoma.
    Trabucco SE; Gerstein RM; Evens AM; Bradner JE; Shultz LD; Greiner DL; Zhang H
    Clin Cancer Res; 2015 Jan; 21(1):113-22. PubMed ID: 25009295
    [TBL] [Abstract][Full Text] [Related]  

  • 71. JQ1: a novel potential therapeutic target.
    Shi X; Liu C; Liu B; Chen J; Wu X; Gong W
    Pharmazie; 2018 Sep; 73(9):491-493. PubMed ID: 30223929
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Low-dose triptolide enhances antitumor effect of JQ1 on acute myeloid leukemia through inhibiting RNA polymerase II in vitro and in vivo.
    Shi Y; Zhao H; Ye J; Li Z; Deng M; Zha J; Zhou Y; Zeng H; Lin Y; Pu X; Guo C; Song H; Qiu Y; Xu B
    Mol Carcinog; 2020 Sep; 59(9):1076-1087. PubMed ID: 32691884
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Bromodomain and extraterminal (BET) protein inhibition suppresses human T cell leukemia virus 1 (HTLV-1) Tax protein-mediated tumorigenesis by inhibiting nuclear factor κB (NF-κB) signaling.
    Wu X; Qi J; Bradner JE; Xiao G; Chen LF
    J Biol Chem; 2013 Dec; 288(50):36094-105. PubMed ID: 24189064
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Vitamin C Sensitizes Melanoma to BET Inhibitors.
    Mustafi S; Camarena V; Volmar CH; Huff TC; Sant DW; Brothers SP; Liu ZJ; Wahlestedt C; Wang G
    Cancer Res; 2018 Jan; 78(2):572-583. PubMed ID: 29180474
    [TBL] [Abstract][Full Text] [Related]  

  • 75. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.
    Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J
    Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Resistance to everolimus driven by epigenetic regulation of MYC in ER+ breast cancers.
    Bihani T; Ezell SA; Ladd B; Grosskurth SE; Mazzola AM; Pietras M; Reimer C; Zinda M; Fawell S; D'Cruz CM
    Oncotarget; 2015 Feb; 6(4):2407-20. PubMed ID: 25537515
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Bromodomain protein BRD4 promotes cell proliferation in skin squamous cell carcinoma.
    Xiang T; Bai JY; She C; Yu DJ; Zhou XZ; Zhao TL
    Cell Signal; 2018 Jan; 42():106-113. PubMed ID: 29050985
    [TBL] [Abstract][Full Text] [Related]  

  • 78. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia.
    Zuber J; Shi J; Wang E; Rappaport AR; Herrmann H; Sison EA; Magoon D; Qi J; Blatt K; Wunderlich M; Taylor MJ; Johns C; Chicas A; Mulloy JC; Kogan SC; Brown P; Valent P; Bradner JE; Lowe SW; Vakoc CR
    Nature; 2011 Aug; 478(7370):524-8. PubMed ID: 21814200
    [TBL] [Abstract][Full Text] [Related]  

  • 79. BET Bromodomain Inhibition Potentiates Ocular Melanoma Therapy by Inducing Cell Cycle Arrest.
    Chen X; Huang R; Zhang Z; Song X; Shen J; Wu Q
    Invest Ophthalmol Vis Sci; 2024 Jul; 65(8):11. PubMed ID: 38967943
    [TBL] [Abstract][Full Text] [Related]  

  • 80. BRD4-targeted therapy induces Myc-independent cytotoxicity in Gnaq/11-mutatant uveal melanoma cells.
    Ambrosini G; Sawle AD; Musi E; Schwartz GK
    Oncotarget; 2015 Oct; 6(32):33397-409. PubMed ID: 26397223
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.